Stoneridge Investment Partners LLC lowered its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 60.2% during the second quarter, Holdings Channel reports. The fund owned 104,932 shares of the biopharmaceutical company’s stock after selling 158,798 shares during the period. Stoneridge Investment Partners LLC’s holdings in TG Therapeutics were worth $1,055,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in TGTX. FMR LLC boosted its stake in TG Therapeutics by 70.2% in the first quarter. FMR LLC now owns 6,451,713 shares of the biopharmaceutical company’s stock worth $75,162,000 after buying an additional 2,660,949 shares during the period. Jennison Associates LLC bought a new stake in shares of TG Therapeutics during the first quarter worth approximately $16,034,000. EAM Investors LLC bought a new stake in shares of TG Therapeutics during the first quarter worth approximately $3,856,000. Vanguard Group Inc. boosted its stake in shares of TG Therapeutics by 16.0% in the first quarter. Vanguard Group Inc. now owns 1,790,583 shares of the biopharmaceutical company’s stock worth $20,860,000 after buying an additional 246,404 shares during the last quarter. Finally, Columbus Circle Investors boosted its stake in shares of TG Therapeutics by 29.3% in the first quarter. Columbus Circle Investors now owns 1,004,421 shares of the biopharmaceutical company’s stock worth $11,702,000 after buying an additional 227,722 shares during the last quarter. 45.68% of the stock is currently owned by hedge funds and other institutional investors.
TG Therapeutics, Inc. (NASDAQ TGTX) opened at 10.15 on Thursday. The company’s market capitalization is $625.81 million. The company’s 50-day moving average price is $10.99 and its 200-day moving average price is $9.95. TG Therapeutics, Inc. has a 52 week low of $4.10 and a 52 week high of $15.35.
TRADEMARK VIOLATION WARNING: “TG Therapeutics, Inc. (TGTX) Shares Sold by Stoneridge Investment Partners LLC” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/2796455/tg-therapeutics-inc-tgtx-shares-sold-by-stoneridge-investment-partners-llc.html.
A number of brokerages have commented on TGTX. Jefferies Group LLC restated a “buy” rating and issued a $23.00 price target on shares of TG Therapeutics in a research report on Monday, June 5th. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research cut TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. Finally, FBR & Co restated a “buy” rating on shares of TG Therapeutics in a research report on Thursday, May 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $23.67.
In other TG Therapeutics news, CFO Sean A. Power sold 59,976 shares of the business’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $11.09, for a total transaction of $665,133.84. Following the completion of the sale, the chief financial officer now directly owns 477,464 shares in the company, valued at approximately $5,295,075.76. The transaction was disclosed in a document filed with the SEC, which is available through this link. 16.70% of the stock is currently owned by insiders.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX).
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.